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MRI magnetic resonance imaging 
MRS magnetic resonance spectroscopy 
IMZ  iomazenil 
SPECT  single photon emission computed tomography 
EEG electroencephalogram 
GABA γ-aminobutyric acid 
MRA magnetic resonance angiography  
PRESS Point Resolved Spectroscopy 
CHESS chemical shift-selective 
TR repetition time 
TE echo time 
ROI region of interest 
NAA N-acetyl aspartate 
Glu glutamate 
%SD  percent standard deviation  
STEAM stimulated echo acquisition mode  
Cr  creatinine  
mIns  myo-inositol  




Since neuroradiological features of patients with 22q11.2 deletion syndrome 
are not well-understood, examinations using functional imaging were performed in this 
study.  
Brain magnetic resonance imaging(MRI) and 1H-magnetic resonance 
spectroscopy(MRS) were performed using a clinical 3-tesla MR imager in 4 patients 
with 22q11.2 deletion syndrome (2 boys and 2 girls; 2~6 years.) and 20 age- and 
sex-matched healthy control subjects. Furthermore, interictal 123I- iomazenil (IMZ) 
single photon emission computed tomography(SPECT) was examined in two of the four 
patients.  
Among 4 patients with 22q11.2 deletion syndrome, 2 patients showed 
polymicrogyria and 1 patient showed agyria. Those patients with brain malformations 
also showed abnormal brain artery and decreased accumulation of IMZ in 123I-IMZ 
SPECT. Although all 4 patients showed epileptic discharges in 
electroencephalogram(EEG), one patient with polymicrogyria had no seizure episode. 
Decreases inγ-aminobutyric acid(GABA) corresponding to the areas of polymicrogyria 
and/or epileptic discharges in EEG were shown in all patients except for the patient 
with agyria. 
Although consistent evidence was not seen in patients with 22q11.2 deletion 
syndrome in this study, brain malformations and disturbances of the GABAergic 
nervous system would be underlying mechanisms of the neurodevelopmental 
abnormalities in this syndrome. 
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Chromosome 22q11.2 deletion syndrome is seen in 1 in 4000 to 1 in 5000 
children. Individuals with 22q11.2 deletion syndrome are characterized by a 
considerable variety of clinical manifestations, including congenital heart disease 
(74%)[18], palatal abnormalities (69%)[19], characteristic facial features (hooded eyelids, 
a prominent nasal root with a bulbous nasal tip, hypoplastic alae nasae, and auricular 
abnormalities ) [20].  Seventy-seven percent of individuals have an immune deficiency 
regardless of their clinical presentation [29].  Additional findings include hypocalcemia 
(9%), renal anomalies (11.6%), and skeletal abnormalities (9.3%)[1]. 
Although patients with this syndrome show either of the deletion sizes with 
1.5-Mb or 3-Mb, their phenotypic features are not different by the different deletion 
sizes  [32] .  Nucleotide alterations of TBX1 have been found in individuals with 
mimicking clinical phenotype with 22q11.2 deletion syndrome but no chromosomal 
deletion of 22q11.2 [32]. Therefore, TBX1 is considered as a major genetic determinant 
for some of the phenotypic features of 22q11.2 deletion syndrome. Some other genes 
included in the deletion region would contribute to the phenotype. 
In 22q11.2 deletion syndrome, many neurologic abnormalities have been 
identified (e.g., developmental delay in infancy 75% , behavioral or psychiatric problems 
9-50%, attention deficit hyperactivity disorder 25%, schizophrenia 6-30%, and speech 
delay 79-84%) [14]. However, the complication of epilepsy including recurrent, 
apparently unprovoked seizures is not well known. Kao et al, investigated 348 patients 
with 22q11.2 deletion syndrome at the Children's Hospital of Philadelphia, 27 patients 
(7%) had apparently unprovoked seizures [12].  This is much greater than estimates in 
the literature of the prevalence of epilepsy in children up to age 20 years, which range 
between 2.8 and 20.7 per 1,000.［8］.  Kao et al, also investigated the possibility that the 
occurrence of unprovoked seizures was secondary to effects of cardiac disease, family 
history of epilepsy, or prematurity, but none of these were significant risk factors for 
development of unprovoked seizures in individuals with a 22q11.2 deletion syndrome. 
In patients with 22q11.2 deletion syndrome, polymicrogyria has been the most 
frequently reported brain malformation on MRI.  But the other brain malformations 
have also been described with 22q11.2 deletion syndrome such as corpus callosum, 
cerebellar atrophy.[26] Since the functional characteristics of the brain lesions and 
epileptogenesis in 22q11.2 deletion syndrome are not yet well established, examinations 




・Patients and Methods 
Patients  
Four patients with 22q11.2 deletion syndrome (2 boys and 2 girls: 2~6 years 
old) were included in the subjects of this study. 
 The control subjects for 1H- magnetic resonance spectroscopy(MRS)  
consisted of 20 age and sex matched healthy control subjects(10 boys and 10 girls, 2-6 
years). The control subjects complained of nonspecific temporal symptoms, such as 
headache, but showed no neurologic findings and no anatomical abnormalities by 
magnetic resonance imaging(MRI).  
Clinical informations of the patients are summarized in Table1. The three of 
four patients suffered from epilepsy when the study was performed, and were receiving 





Brain MRI and 1H-MRS using a clinical 3-tesla MR imager were performed. All 
subjects were treated with triclofos sodium (Tricloryl; 0.5 ml/kg body weight) for 
sedation one hour before MR examination.  All measurements were performed with a 
clinical 3-tesla MR imager (Signa 3T HD, GE Medical Systems, Milwaukee, WI, USA) 
using a standard quadrature head coil for MRI, magnetic resonance angiography (MRA) 
and 1H-MRS measurements.  The criteria for hypoplasia of the intracranial artery at 
our institution are the existence of more than 50% partial laterality of vascular 
diameters and clear laterality of the degree of the depiction of peripheral vessels. For 
1H-MRS, in the control subjects, by using a three-dimensional image, an axial image 
approximately 5mm above the upper end of the corpus callosum was selected, and the 
center of a voxel was positioned in the left inferior frontal gyrus and the posterior 
margin of a voxel was placed ahead of the central sulcus. Metabolite concentrations in 
normal controls are described in Table2. 
In the patients with 22q11.2 deletion syndrome, a single voxel was set on the 
image of a cortical dysplasia lesion of the inferior frontal gyrus. Furthermore, another 
voxel was set on the contralateral normal-appearing brain region.  
MEGA was incorporated into Point Resolved Spectroscopy (PRESS) consistent 
with the protocol established in previous reports [21,22].  Water suppression was 
carried out using conventional three chemical shift-selective (CHESS) pulses after 
manual optimization, and was achieved at a level of less than 1%.  Gradient map 
shimming was conducted in the measurement location by the high-order shim program, 
and the full width at half maximum of the water peak was less than 7 Hz.  The 
sequence parameters were as follows: repetition time(TR) = 2500 ms, echo time(TE) = 
68 ms, region of interest (ROI) = 2.5×2.5×2.5cm3 (15.6 ml), summation = 128 signals for 
each spectrum, total acquisition time = 12 minutes.  Measurements with and without 
frequency-selective pulses were conducted alternatively, i.e., J evolution for GABA was 
refocused during odd-numbered acquisitions, and was not refocused during 
even-numbered acquisitions.  Phase correction was conducted for each spectrum.  
Differences in the acquired spectra provided an edited spectrum for GABA. The in vitro 
data for N-acetyl aspartate (NAA), glutamate (Glu), andγ-aminobutyric acid (GABA) 
were acquired with MEGA-PRESS with the same parameters as for human 
measurements and set according to the LCModel basis set.  Signals in J-difference 
edited spectra obtained by MEGA-PRESS were analyzed by LCModel (version 6.1) with 
our original basis set and quantification of the GABA level was based on the 
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unsuppressed water signal obtained from the same voxel assuming a water content of 
82%, according to previous reports [6,24].  Based on findings in previous studies [30], 
the T2 relaxation effects were assumed to have negligible influence on quantification, 
although the T1 relaxation effects were compensated for according to literature 
values[2,6].  The criteria for selecting reliable metabolite concentrations were based on 
the percent standard deviation (%SD) of the fit for each metabolite that reflected the 
Cramer-Rao lower bounds. Only results with a %SD <15% were included in the 
analysis.  
  The parameters of the conventional stimulated echo acquisition mode 
(STEAM) sequence were as follows: TR = 5000 ms, TE = 15 ms, ROI = 2.5×2.5×2.5 cm3 
(15.6 ml), total acquisition time = 6.8 minutes.  Before we used LCModel, an original 
basis-set matched with the STEAM sequence was made from the in vitro measurements 
of each chemical: GABA, Glu, NAA, n-acetylaspartylglutamate, creatinine (Cr), 
myo-inositol (mIns), glycerophosphocholine, phosphorylcholine, glycine, taurine, glucose, 
lactate and macromolecules.  The metabolites, NAA, choline-containing compounds 
(Cho), Cr, mIns, and Glu were analyzed with the use of an internal water calibration 
method in LCModel.  The %SD value of the fit for each metabolite that reflected the 
Cramer-Rao lower bounds was less than 15%. The concentration of each metabolite was 
judged to be abnormal when the value was higher or lower than 2SD of that in the 
control subjects.  
Two of the four patients were also examined by single photon emission computed 
tomography(SPECT) with 123I- iomazenil (IMZ). 123I-IMZ is a ligand that binds to 
central benzodiazepine receptor (BZR).  BZR and the GABAA receptor form a complex, 
and therefore we can obtain information about the GABA receptor indirectly by 123I-IMZ 
SPECT. Images were obtained 180 minutes after the administration of 123I-IMZ at a 
dose of 167 MBq.  All patients were treated with triclofos sodium (Tricloryl; 0.5 ml/kg 
body weight) for sedation one hour before the SPECT measurement.  The SPECT 
measurement was conducted with a two-head gamma camera scanner (E.CAM: Toshiba, 
Tokyo, Japan) with a fan beam collimator, a Butterworth filter, and filtered back 
projection (matrix size = 64x64: voxel size = 3.4 mm). 
This study was approved by the Institutional Review Board of our institution, 









In Patients 1-3, 1H-MRS showed no remarkable changes in the concentrations 
of NAA, Cho, Cr, Glu or mIns, as well as no obvious lactate peak (Table 2). 
 
Patient 1   
 A 3 years old boy at examination. On brain MRI (Figure 1-1), regional loss of 
the normal gyral pattern and a mildly thick cortex predominantly in the left frontal to 
parietal lobe were detected. Therefore, we diagnosed his brain malformation as 
polymicrogyria.  On MRA（Figure 2-1）, hypoplasia of the left internal carotid artery 
and left middle cerebral artery was detected. 1H-MRS (Figure 3, Table 2) showed a 
decreased concentration of GABA (0.31mM) at the polymicrogyria, compared with those 
in normal controls and that in his contralateral frontal region, where polymicrogyria 
was not observed. On 123I-IMZ SPECT (Figure 4a), a slight decrease in the accumulation 
of 123I-IMZ was seen in the polymicrogyria part. 
 
Patient 2   
A 6 years old girl at examination. No abnormal findings were seen by brain 
MRI (Figure 1-2) or MRA（Figure 2-2）.  On 1H-MRS (Table 2), a decrease in the 
concentration of GABA (0.43mM) was seen in the left frontal lobe where epileptic 
discharges were detected on interictal electroencephalogram(EEG), compared with 
those in normal controls and that in her contralateral frontal region where an EEG 
abnormality was not observed.  
 
Patient 3   
A 2 years old girl at examination. On brain MRI (Figure 1-3), a regional loss of 
the normal gyral pattern and a mildly thick cortex in the right cerebral hemisphere 
were detected. Therefore, we diagnosed her brain malformation as polymicrogyria.  
MRA（Figure 2-3） showed  hypoplasia of the right middle cerebral artery and right 
posterior cerebral artery.  1H-MRS (Table2) showed a decrease in the concentration of 
GABA (0.45mM) in polymicrogyria, compared with those in normal controls and that in 
her contralateral frontal region, where polymicrogyria was not observed.  
 
Patient 4   
A 2 years old boy at the 1st examination. On brain MRI (Figure 1-4), the 
surface of the bilateral frontal lobes was smooth, and we diagnosed his brain 
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malformation as agyria.  On MRA（2-4）, hypoplasia of the right middle cerebral artery 
was seen.  By 1H-MRS (Table 2), a decrease in the concentration of NAA (3.4mM) and 
an increase in the concentration of GABA (1.5mM) were seen in the agyria region, 
compared with those in normal controls.  No remarkable changes were seen in the 
concentrations of Cho, Cr, Glu and mIns.  An obvious lactate peak was not detected. 
At age 3 years, brain MRI was rechecked and 123I-IMZ SPECT was performed.  
In this second brain MRI (T1-weighted image) (Figure 4b), laminar necrosis of the right 
parieto-occipital lobe was noted.  On 123I-IMZ SPECT (Figure 4b), a complete absence 
of 123I-IMZ accumulation was noted in the right parieto-occipital cortical necrosis. In the 















In patients with 22q11.2 deletion syndrome, polymicrogyria has been the most 
frequently reported brain malformation other than agenesis of the corpus callosum, 
cerebellar atrophy and meningomyelocele [26]. There was a previous large study for 32 
patients with 22q11.2 deletion syndrome associated with polymicrogyria, in which 
broad range of severity and frequent association with asymmetry with a striking 
predisposition for the right hemisphere were shown [26]. The patients with 22q11.2 
deletion syndrome associated with polymicrogyria showed variable neurological 
findings including developmental delay, hemiplegia, seizure, pseudobulbar palsy, and 
muscular tonus abnormality. Thus, patients with 22q11.2 deletion syndrome associated 
with such atypically severe neurological findings should be evaluated by 
neuroradiological examinations. 
The etiology of polymicrogyria in this syndrome has not been well-understood. 
The most attractive finding is asymmetrical occurrence between hemispheres, which 
may be a consequence of asymmetrical expression of the responsible genes for cortical 
dysgenesis [4,5,7,13,26,27,33]. Another possible and more intriguing mechanism of 
polymicrogyria involves hypoperfusion of the embryonic brain. Some cases of 
polymicrogyria were considered as the results of postmigrational insults including 
infections and vascular abnormalities [4,7]. 
Haploinsufficiency of TBX1 results in a spectrum of distinct vascular and heart 
defects in both mouse and human that affect the formation and growth of pharyngeal 
arch arteries and related structures [17,32]. In the present study, MRA revealed 
hypoplasia of the intracranial artery on the ipsilateral side of polymicrogyria in patient 
1 and 3. This evidence suggested that polymicrogyria would be the consequence of 
vascular dysgenesis in these patients. 
Epileptic seizures are considered to be a consequence of the relative imbalance 
between excitatory and inhibitory neurotransmission [9], which would precipitate 
hyperexcitability and an abnormally reduced concentration of GABA.  Increased 
glutamatergic projection from the polymicrogyria to surrounding areas, which forms an 
extensive excitatory network, has been assumed to exist in epileptogenesis in this 
condition.  Studies in laboratory animals have shown increases in postsynaptic 
Glu(excitatory) receptors and decreases in GABAA (inhibitory) receptors in the 
polymicrogyria cortex [10], and these changes likely promote epileptogenesis. 
Previously, 123I-IMZ SPECT showed low accumulations corresponding to 
epileptogenic foci associated with focal cortical dysplasia and temporal lobe epilepsy 
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[23].   In this study, 123I-IMZ SPECT in patient 1 showed a low accumulation of IMZ in 
the polymicrogyria region, which may indicate that epileptogenesis in patients with 
22q11.2 deletion syndrome was caused by decreased inhibition secondary to a decrease 
in GABA receptor in dysplastic cortex. 
Regarding the results of 1H-MRS, some controversial findings of 
polymicrogyria have been reported [15,16,28,31].  In a previous 1H-MRS study in three 
patients with polymicrogyria, two showed low NAA within the lesion and two showed 
low NAA or a low NAA/Cr ratio in the peri-regional area [31].  An in vivo 1H-MRS 
study for cortical malformation including polymicrogyria and heterotopia showed 
elevated Glu and reduced NAA levels in subjects with cortical malformation [28]. The 
ratio of GABA or GABA +homocarnosine/Cr was also shown to be elevated [28]. In 
contrast, some reports have noted a negative correlation between MRS and 
polymicrogyria tissues [15, 16].  In any case, there has been no report that GABA was 
decreased in polymicrogyria. 
To date, no study has used 1H-MRS in patients with 22q11.2 deletion syndrome. 
In the present study, we identified a reduction in the GABA concentration on the 
ipsilateral side of the polymicrogyria and spike discharges in patients with 22q11.2 
deletion syndrome associated with polymicrogyria (patients 1 and 3).  In contrast, we 
found no significant changes in the concentrations of NAA, Cr, Cho, mIns, or Glu in the 
same patients.  We also found a reduction in the GABA concentration on the ipsilateral 
side of the spike discharges in patient 2, who had no apparent brain malformation.  We 
thought that there may be heterogeneous pathomechanisms of epilepsy in 
polymicrogyria. In patients with 22q11.2 deletion syndrome, this suggests that 
GABAergic neurons may have been more vulnerable than glutamatergic neurons, which 
may be caused by insufficient fetal circulation due to vascular malformations.    
To the best of our knowledge, this is the first report of a patient with 22q11.2 
deletion syndrome associated with agyria(patient 4). Previously, significant reduction of 
NAA was identified in four patients with agyria (lissencephaly)[10], which might 
indicate abnormalities of neurons with either of decreased numbers, immaturity, and 
dysfunction. The same result was shown in the present study for the patient with 
22q11.2 deletion syndrome associated with agyria.   
Additionally, as the first evidence of this type in a patient with agyria, a 
significant increase in GABA was identified in this patient.  A decreased or defective 
population of GABAergic neurons has been neuropathologically proven in lissencephaly 
due to defects in the DCX and ARX genes.[25]. The neuropathological futures and the 
mechanism of the increased GABA concentration in our patient with agyria(patient 4) 
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are unknown. There is a possibility that a significant increase in GABA on 1H-MRS 
might be the consequence of compensation for decrease in GABA(A) receptors, since a 
significant decrease in IMZ binding was identified by 123I-IMZ SPECT.  The brain MRI 
findings in patient 4 with agyria were quite different from those in the other three 
patients.  Therefore, we need to consider the possibility that the cause of cortex 
dysplasia in patient 4 may be different from those in the other patients.  
Patient 4 was administrated clobazam, and therefore we could not exclude the 
possibility that clobazam affected the accumulation of IMZ in this patient.  However, 
we thought that the degree of this decrease in IMZ accumulation was clear and greater 
than the possible effect of clobazam.   
The cause of the parieto-occipital lobe destructive change in the MRI at 3 years 
in patient 4 was not clear, but the increase in the clonic convulsion of the left upper and 
lower limbs was observed just before the onset of this change by MRI.  Only patient 4 
did not undergo a radical operation for heart disease (TOF), and therefore this patient 
may have experienced a frequent and persistent cyanotic attack.  Since the right 
parieto-occipital lobe was a site of vascular hypoplasia, we thought that cerebral 
ischemia due to the cyanotic attack may have caused this change in the image. 
Despite the limited number of patients sample available for this study, the 
decreased concentration of GABA was demonstrated by 1H-MRS in patients with 
22q11.2 deletion syndrome, except for a patient with agyria, and the decreased GABA 
receptors were revealed by 123I-IMZ SPECT in two patients with 22q11.2 deletion 
syndrome. Although consistent evidence was not seen in patients with 22q11.2 deletion 
syndrome in this study, brain malformations and disturbances of the GABAergic 
nervous system would be underlying mechanisms of the neurodevelopmental 
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AED: antiepileptic drug, CBZ: carbamazepine, CHD: congenital heart disease, CLB: clobazam, CPS: complex partial seizure,  
DQ: development quotient, IQ: intelligence quotient, PA: pulmonary atresia PB: phenobarbital, PDA: patent ductus arteriosus, 
TOF: tetralogy of Fallot 
Table 2   
Comparison of metabolite concentrations in the affected cortex, unaffected cortex in the 
same patient, and normal controls by 1H-MRS. 
# : The concentration of each metabolite was higher or lower than 2SD of that in the 
control subjects. 
 




5.4 4.1 1.2 3.6 6.8 #0.31 






5.8 4.0 1.2 2.5 7.4 #0.43 




4.6 3.6 1.3 2.8 6.8 #0.45 






















      





Figure 1.  Brain MRI(T2-weighted image):  
The square shows the region of interest in 1H-MRS. Rt:right, Lt:left. 
1. Patient 1 :Regional loss of the normal gyral pattern and a mildly thick cortex 
predominantly in the left frontal to parietal lobe were detected.  Therefore, we 
gave a diagnosis of polymicrogyria.  
2. Patient 2: No remarkable change was found.  
3. Patient 3: Regional loss of the normal gyral pattern and a mildly thick cortex in 
the right cerebral hemisphere were detected.  Therefore, we gave a diagnosis of 
polymicrogyria.  
4. Patient 4: The surface of the bilateral frontal lobes was smooth, and therefore we 
gave a diagnosis of agyria.   
 
 
Figure 2.    magnetic resonance angiography (MRA) 
Rt:right, Lt:left.  
1. Patient 1: Hypoplasia of the left arteria carotis interna and left middle cerebral 
artery was detected.  
2. Patient 2: No remarkable change was found. 
3. Patient 3: Hypoplasia of the right middle cerebral artery and right posterior 
cerebral artery was detected. 




Figure 3.   1H-MRS (Patient 1)  
STEAM method(upper spectra): No remarkable change was found in the bilateral 
frontal lobes.  
MEGA-PRESS method(lower spectra): A decrease in the concentration of GABA 
(0.31mM) in polymicrogyria was seen, compared with those in normal controls and 





Figure 4   123I-IMZ SPECT and Brain MRI 
Rt:right, Lt:left.  
a  : Patient 1  
123I-IMZ SPECT : A slight decrease in the accumulation of 123I-IMZ was seen in the  
polymicrogyria region. (arrow) 
b  : Patient 4  
Results of the second brain MRI (age 3 years, T1-weighted image):  Laminar necrosis 
of the right parietal and occipital lobes was seen.  
123I-IMZ SPECT (age 3 years):  A complete absence of the accumulation of 123I-IMZ 
was seen in the right parietal and occipital cortical necrosis.(arrowhead)  In the 
agyria region, the accumulation of 123I-IMZ was reduced.(arrow)  
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